Zarkowsky Devin S, Hicks Caitlin W, Bostock Ian C, Stone David H, Eslami Mohammad, Goodney Philip P
Division of Vascular and Endovascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
Department of Surgery, The Johns Hopkins Medical Institutes, Baltimore, Md.
J Vasc Surg. 2016 Nov;64(5):1278-1285.e1. doi: 10.1016/j.jvs.2016.04.009. Epub 2016 Jul 29.
The reported frequency of renal dysfunction after elective endovascular aneurysm repair (EVAR) varies widely in current surgical literature. Published research establishes pre-existing end-stage renal disease as a poor prognostic indicator. We intend to quantify the mortality effect associated with renal morbidity developed postoperatively and to identify modifiable risk factors.
All elective EVAR patients with preoperative and postoperative renal function data captured by the Vascular Quality Initiative between January 2003 and December 2014 were examined. The primary study end point was long-term mortality. Preoperative, intraoperative, and postoperative parameters were analyzed to estimate mortality stratified by renal outcome and to describe independent risk factors associated with post-EVAR renal dysfunction.
This study included 14,475 elective EVAR patients, of whom 96.8% developed no post-EVAR renal dysfunction, 2.9% developed acute kidney injury, and 0.4% developed a new hemodialysis requirement. Estimated 5-year survival was significantly different between groups, 77.5% vs 53.5%, respectively, for the no dysfunction and acute kidney injury groups, whereas the new hemodialysis group demonstrated 22.8% 3-year estimated survival (P < .05). New-onset postoperative congestive heart failure (odds ratio [OR], 3.50; 95% confidence interval [CI], 1.18-10.38), return to the operating room (OR, 3.26; 95% CI, 1.49-7.13), and postoperative vasopressor requirement (OR, 2.68; 95% CI, 1.40-5.12) predicted post-EVAR renal dysfunction, whereas a preoperative estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m was protective (OR, 0.33; 95% CI, 0.21-0.53). Volume of contrast material administered during elective EVAR varies 10-fold among surgeons in the Vascular Quality Initiative database, but the average volume administered to patients is statistically similar, regardless of preoperative eGFR. Multivariable logistic regression demonstrated nonsignificant correlation between contrast material volume and postoperative renal dysfunction.
Any renal dysfunction developing after elective EVAR is associated with decreased estimated long-term survival. Protecting renal function with a rational dosing metric for contrast material linked to preoperative eGFR may better guide treatment.
在当前外科文献中,择期血管腔内动脉瘤修复术(EVAR)后肾功能障碍的报告发生率差异很大。已发表的研究表明,术前存在终末期肾病是一个不良预后指标。我们旨在量化术后发生的肾脏疾病相关的死亡影响,并确定可改变的风险因素。
对2003年1月至2014年12月期间由血管质量倡议组织收集了术前和术后肾功能数据的所有择期EVAR患者进行检查。主要研究终点是长期死亡率。分析术前、术中和术后参数,以估计按肾脏结局分层的死亡率,并描述与EVAR术后肾功能障碍相关的独立危险因素。
本研究纳入了14475例择期EVAR患者,其中96.8%未发生EVAR术后肾功能障碍,2.9%发生急性肾损伤,0.4%出现新的血液透析需求。无功能障碍组和急性肾损伤组的估计5年生存率有显著差异,分别为77.5%和53.5%,而新的血液透析组的3年估计生存率为22.8%(P<0.05)。术后新发充血性心力衰竭(比值比[OR],3.50;95%置信区间[CI],1.18 - 10.38)、返回手术室(OR,3.26;95%CI,1.49 - 7.13)和术后血管升压药需求(OR,2.68;95%CI,1.40 - 5.12)可预测EVAR术后肾功能障碍,而术前估计肾小球滤过率(eGFR)≥60 mL/min/1.73 m²具有保护作用(OR,0.33;95%CI,0.21 - 0.53)。在血管质量倡议数据库中,不同外科医生在择期EVAR期间使用的造影剂体积相差10倍,但无论术前eGFR如何,给予患者的平均体积在统计学上相似。多变量逻辑回归显示造影剂体积与术后肾功能障碍之间无显著相关性。
择期EVAR后发生的任何肾功能障碍都与估计的长期生存率降低相关。采用与术前eGFR相关的合理造影剂给药指标来保护肾功能可能更好地指导治疗。